Pharming Group to participate in February investor conference
Pharming Group (Nasdaq: PHAR) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pharming Group (Nasdaq: PHAR) has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The virtual event will feature a presentation by CEO Sijmen de Vries and CMO Anurag Relan on Wednesday, February 12 at 08:40 ET/14:40 CET.
Investors can access both the live webcast and replay of the presentation through the 'Upcoming Events' and 'News' sections of Pharming's website. Those interested in scheduling one-to-one meetings with Pharming's management team can contact the company's Investor Relations team or their Oppenheimer representative.
Details
News Market Reaction – PHAR
On Feb 10, the day this news came out, PHAR closed 0.07% below the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of February:
- Oppenheimer 35th Annual Healthcare Life Sciences Conference, Virtual, February 11-12, 2025
Sijmen de Vries, Chief Executive Officer and Anurag Relan, Chief Medical Officer, will present on Wednesday, February 12 at 08:40 ET/14:40 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Oppenheimer representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.